Annual Reports In Medicinal Chemistry by Manoj C DesaiAnnual Reports In Medicinal Chemistry by Manoj C Desai

Annual Reports In Medicinal Chemistry

byManoj C DesaiEditorManoj C Desai

Paperback | September 24, 2014

Pricing and Purchase Info

$234.40 online 
$255.94 list price
Earn 1,172 plum® points

Prices and offers may vary in store

Out of stock online

Not available in stores


Annual Reports in Medicinal Chemistryprovides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies.

  • Reviews on hot topics of interest in small molecule drug discovery heavily pursued by industrial research organizations
  • Provides preclinical information in the context of chemical structures
  • Knowledgeable section editors who evaluate invited reviews for scientific rigor
Dr. Manoj Desai began his career in the pharmaceutical industry at Pfizer Inc, Central Research Division, Groton, CT (1986-1994) before moving to Chiron Corporation (1994-2003) as Director of medicinal chemistry; he was promoted to Vice President, lead discovery and medicinal chemistry (2000). In October 2003, he was appointed Vice Pre...
Title:Annual Reports In Medicinal ChemistryFormat:PaperbackDimensions:636 pages, 8.75 × 6.35 × 0.68 inPublished:September 24, 2014Publisher:Academic PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0128001674

ISBN - 13:9780128001677


Table of Contents

  1. A Personal Essay: My Experiences in the Pharmaceutical Industry
  2. Adventures in Medicinal Chemistry - A Career in Drug Discovery
  3. Natural and Synthetic Neuroactive Steroid (NAS) Modulators of GABAAand NMDA Receptors
  4. Development of LRRK2 Kinase Inhibitors for Parkinson's Disease
  5. Stimulating Neurotrophin Receptors in the Treatment of Neurodegenerative Disorders
  6. Small Molecule Modulators of GPR40 (FFA1)
  7. Recent Advances in the Development of P2Y12Receptor Antagonists as Antiplatelet Agents
  8. Current Approaches to the Treatment of Atrial Fibrillation
  9. Advances in the Discovery of Small Molecule IRAK4 Inhibitors
  10. H4Receptor Antagonists and Their Potential Therapeutic Applications
  11. Urate Crystal Deposition Disease and Gout - New Therapies for an Old Problem
  12. p53 - MDM2 and MDMX Antagonists
  13. Modulators of Atypical Protein Kinase C as Anticancer Agents
  14. Advancement of Cell Wall Inhibitors inMycobacterium Tuberculosis
  15. Nucleosides and Nucleotides for the Treatment of Viral Diseases
  16. Advances in Inhibitors of Penicillin Binding Proteins and ß-lactamases as Antibacterial Agents
  17. Tumor Microenvironment as Target in Cancer Therapy
  18. Novel Screening Paradigms for the Identification of Allosteric Modulators and /or Biased Ligands for Challenging G-Protein-Coupled Receptors (GPCRs)
  19. Mer Tyrosine Kinase Receptor: Therapeutic Opportunities in Oncology, Virology and Cardiovascular Indications
  20. Disease Modifying Agents for the Treatment of Cystic Fibrosis
  21. Advancements in Stapled Peptide Drug Discovery and Development
  22. Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development
  23. Case History: ForxigaTM(Dapagliflozin), a Potent Selective SGLT2 Inhibitor for Treatment of Diabetes
  24. Case History: Kalydeco® (VX-770, Ivacaftor), a CFTR Potentiator for the Treatment of Patients with Cystic Fibrosis and theG551D-CFTRMutation
  25. Case History: XeljanzTM(Tofacitinib Citrate), A First-In-Class Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis
  26. New Chemical Entities Entering Phase III Trials in 2013
  27. To Market, To Market 2013